Tian Zhang, MD
@tiansterzhangmd.bsky.social
I treat & research GU cancers @UTSW in Dallas. Columbia/Harvard Med/Duke alum; Mom & wife
Posts=my opinions
ASCO COI: https://coi.asco.org/share/3UF-6U3Z/Tian%20Zhang
Posts=my opinions
ASCO COI: https://coi.asco.org/share/3UF-6U3Z/Tian%20Zhang
#ShahneenSandhu on collaborative efforts with industry partners - how do we maximize time & effort to make industry supported IITs and large phase 3 trials for clinical development. @anzuptrials.bsky.social #ANZUP25
July 19, 2025 at 11:45 PM
#ShahneenSandhu on collaborative efforts with industry partners - how do we maximize time & effort to make industry supported IITs and large phase 3 trials for clinical development. @anzuptrials.bsky.social #ANZUP25
@profiand.bsky.social with key insights to large trial and grant funding in Australia — trial impact, equity in diverse populations, cost effectiveness, patient advocate/consumer involvement, and feasibility @anzuptrials.bsky.social #ANZUP25
July 19, 2025 at 11:28 PM
@profiand.bsky.social with key insights to large trial and grant funding in Australia — trial impact, equity in diverse populations, cost effectiveness, patient advocate/consumer involvement, and feasibility @anzuptrials.bsky.social #ANZUP25
Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social
July 19, 2025 at 11:19 PM
Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social
Proud of our #UTSWcancer clinical research teams displaying our cancer center’s ongoing work in clinical trials @aacicancer.bsky.social #CRI25 meeting today! Clinical trials are essential to improving outcomes for our patients with cancer - here to network & learn best practices!
June 24, 2025 at 2:46 AM
Proud of our #UTSWcancer clinical research teams displaying our cancer center’s ongoing work in clinical trials @aacicancer.bsky.social #CRI25 meeting today! Clinical trials are essential to improving outcomes for our patients with cancer - here to network & learn best practices!
The connections built within ASCO transcend our daily institutions, across borders, across disease types. We are in this together and we will come out stronger for it — we must, for our patients. See y’all soon @ascocancer.bsky.social #ASCO25 #FIN
May 30, 2025 at 11:53 AM
The connections built within ASCO transcend our daily institutions, across borders, across disease types. We are in this together and we will come out stronger for it — we must, for our patients. See y’all soon @ascocancer.bsky.social #ASCO25 #FIN
The global community comes together for 5 days #ASCO25 to share our work and our advances for our patients. Cancer knows no boundaries and knowledge will empower each of us in daily work ahead. @ASCO
May 30, 2025 at 11:52 AM
The global community comes together for 5 days #ASCO25 to share our work and our advances for our patients. Cancer knows no boundaries and knowledge will empower each of us in daily work ahead. @ASCO
Traveling w/ mixed emotions to @asco #asco25 this yr. Celebrating science & the yrs of dedication, work, & patient contributions to cancer clinical trials. But science itself is under attack — defunding of preclinical discovery work will end up slowing our clinical advances. 1/n
May 30, 2025 at 11:50 AM
Traveling w/ mixed emotions to @asco #asco25 this yr. Celebrating science & the yrs of dedication, work, & patient contributions to cancer clinical trials. But science itself is under attack — defunding of preclinical discovery work will end up slowing our clinical advances. 1/n
Plenary session with @MarcelaMaus @MGHCancerCenter on future CAR-T cells — setting vision toward personalized, patient centered approaches to find the right CARTs. #AACR25 @oncoalert.bsky.social @theaacr.bsky.social
April 28, 2025 at 2:08 PM
Plenary session with @MarcelaMaus @MGHCancerCenter on future CAR-T cells — setting vision toward personalized, patient centered approaches to find the right CARTs. #AACR25 @oncoalert.bsky.social @theaacr.bsky.social
A great start to #UTChrisWood25 - localized RCC discussions from diagnosis (ccRCC score) & novel tracers to treatment of surgery, SBRT, & ablation. #IvanPedrosa #ChadTang #JoseKaram #IsamuTachibana #mohamedabdelsalam & interactive panel discussion!
April 4, 2025 at 5:33 PM
A great start to #UTChrisWood25 - localized RCC discussions from diagnosis (ccRCC score) & novel tracers to treatment of surgery, SBRT, & ablation. #IvanPedrosa #ChadTang #JoseKaram #IsamuTachibana #mohamedabdelsalam & interactive panel discussion!
@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25
February 14, 2025 at 5:07 PM
@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25
#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25
February 14, 2025 at 4:51 PM
#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25
#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25
February 14, 2025 at 4:44 PM
#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25
Mevrometostat with enzalutamide vs enza alone with nice PSA responses and good PFS benefit! @ascocancer.bsky.social #GU25
February 14, 2025 at 1:35 AM
Mevrometostat with enzalutamide vs enza alone with nice PSA responses and good PFS benefit! @ascocancer.bsky.social #GU25
#TanyaDorff w always thoughtful w discussion for metastatic #prostatecancer — buckets of treatments - doublets, triplets, XRT, including trials! #TRIPLESWITCH, #ADREAM, S1802, & more! @ascocancer.bsky.social #GU25
February 13, 2025 at 5:19 PM
#TanyaDorff w always thoughtful w discussion for metastatic #prostatecancer — buckets of treatments - doublets, triplets, XRT, including trials! #TRIPLESWITCH, #ADREAM, S1802, & more! @ascocancer.bsky.social #GU25
#EdwinPosadasMD with eloquent discussion on prostatectomy vs surgery, importance of the #PORTOS biomarker to help define radiation benefit. @ascocancer.bsky.social #GU25
February 13, 2025 at 4:58 PM
#EdwinPosadasMD with eloquent discussion on prostatectomy vs surgery, importance of the #PORTOS biomarker to help define radiation benefit. @ascocancer.bsky.social #GU25
#NeerajAggarwal presents final overall survival from #TALAPRO2 trial - patients w metastatic #prostatecancer lived longer and had improved time to chemo. Only 2 MDS/AML events in entire trial. Supporting the talazoparib-enzalutamide approval. #GU25 @ascocancer.bsky.social
February 13, 2025 at 4:53 PM
#NeerajAggarwal presents final overall survival from #TALAPRO2 trial - patients w metastatic #prostatecancer lived longer and had improved time to chemo. Only 2 MDS/AML events in entire trial. Supporting the talazoparib-enzalutamide approval. #GU25 @ascocancer.bsky.social
George Zhao presents PORTOS score and modeling radiation outcomes. Important to help select patients likely to benefit from XRT. @ascocancer.bsky.social #GU25
February 13, 2025 at 4:23 PM
George Zhao presents PORTOS score and modeling radiation outcomes. Important to help select patients likely to benefit from XRT. @ascocancer.bsky.social #GU25
Tribute to @felixfengmd - Feng Symposium kicks off w @HimanshuNagarMD @mishabeltran @ASCO President-elect #EricSmall at the helm.
Announcing the endowed @ASCO YIA, fostering future scientists and science in #prostatecancer.
We miss you Felix.
Love to @MaryFengMD & family today.
Announcing the endowed @ASCO YIA, fostering future scientists and science in #prostatecancer.
We miss you Felix.
Love to @MaryFengMD & family today.
February 12, 2025 at 9:17 PM
Tribute to @felixfengmd - Feng Symposium kicks off w @HimanshuNagarMD @mishabeltran @ASCO President-elect #EricSmall at the helm.
Announcing the endowed @ASCO YIA, fostering future scientists and science in #prostatecancer.
We miss you Felix.
Love to @MaryFengMD & family today.
Announcing the endowed @ASCO YIA, fostering future scientists and science in #prostatecancer.
We miss you Felix.
Love to @MaryFengMD & family today.
#UTSouthwestern #SimmonsCancerCenter raising community awareness for #prostatecancer this AM - screening “The Silent Killer: Prostate Cancer in the AA Community” — packed room at Light of the World church. Thanks Director #LandiMaduro for coming! m.imdb.com/title/tt3437...
February 1, 2025 at 4:40 PM
#UTSouthwestern #SimmonsCancerCenter raising community awareness for #prostatecancer this AM - screening “The Silent Killer: Prostate Cancer in the AA Community” — packed room at Light of the World church. Thanks Director #LandiMaduro for coming! m.imdb.com/title/tt3437...
This GU oncology family — wonderful first #AUC3 consensus conference!
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
January 24, 2025 at 4:08 AM
This GU oncology family — wonderful first #AUC3 consensus conference!
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social
Awesome panel moderated by #MontyPal #BradMcGregor for non clear cell #Kidneycancer. Histology matters! And so do molecular markers! #AUC3
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social @erplimackmd.bsky.social
January 23, 2025 at 9:08 PM
Awesome panel moderated by #MontyPal #BradMcGregor for non clear cell #Kidneycancer. Histology matters! And so do molecular markers! #AUC3
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social @erplimackmd.bsky.social
#BrianRini & #MikeAtkins debate refractory #kidneycancer management after IO front line or adjuvant PD1 inhibitor. Do we rechallenge? Yes likely after a certain time point (6 vs 12 months debated). #AUC3
January 23, 2025 at 7:10 PM
#BrianRini & #MikeAtkins debate refractory #kidneycancer management after IO front line or adjuvant PD1 inhibitor. Do we rechallenge? Yes likely after a certain time point (6 vs 12 months debated). #AUC3
Drs. #NaomiHaas #HansHammers debate locally advanced #kidneycancer and use of periop immunotherapy. Grading, staging, and prediction of risk/benefit leads to rigorous shared decision making with our patients. @drchoueiri.bsky.social #AUC3
January 23, 2025 at 2:40 PM
Drs. #NaomiHaas #HansHammers debate locally advanced #kidneycancer and use of periop immunotherapy. Grading, staging, and prediction of risk/benefit leads to rigorous shared decision making with our patients. @drchoueiri.bsky.social #AUC3
#BrianShuch kicks us off, local #kidneycancer heterogeneous - guppies, goldfish and sharks! Integrating staging & biomarkers to help us evaluate risk and prognosis. #AUC3
January 23, 2025 at 2:01 PM
#BrianShuch kicks us off, local #kidneycancer heterogeneous - guppies, goldfish and sharks! Integrating staging & biomarkers to help us evaluate risk and prognosis. #AUC3
